Form 4: Baker Bros. Advisors Acquires Pre-Funded Warrants in DBV Technologies Private Placement

Baker Bros. Advisors and related entities acquired pre-funded warrants in DBV Technologies through a private placement expected to close around April 7, 2025.

Summary

• Baker Bros. Advisors LP, along with related entities, has acquired pre-funded warrants in DBV Technologies S.A. through a private placement.
• The transaction involves the purchase of Pre-Funded Warrant Units at a price of EUR1.1136 per unit, with EUR1.1036 pre-funded on the issue date.
• Each Pre-Funded Warrant Unit consists of a pre-funded warrant to purchase an Ordinary Share with an exercise price of EUR0.01 and a warrant to subscribe for one pre-funded warrant at an exercise price of EUR0.9008.
• The private placement is expected to close on or around April 7, 2025.
• The First Pre-Funded Warrants are only exercisable to the extent that the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), no more than 9.99% of the Issuer's outstanding Ordinary Shares (the 'First Pre-Funded Warrant Beneficial Ownership Limitation').
• Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.
• The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a 'Second Pre-Funded Warrant Share') of EUR0.01.
• The Second Pre-Funded Warrants may be exercised until April 7, 2035.

Sentiment

Score: 7

Explanation: The document indicates a significant investment by a reputable firm, suggesting confidence in the company's future. However, the complexity of the warrant structure and ownership limitations introduce some uncertainty.

Positives

• Baker Bros.' investment signals confidence in DBV Technologies' prospects.
• The pre-funded nature of the warrants provides DBV Technologies with immediate capital.
• The warrants have a long expiration date (April 7, 2035), indicating a long-term investment horizon.

Risks

• The exercise of the warrants is subject to beneficial ownership limitations, which could restrict Baker Bros.' ability to fully realize the potential gains.
• The BS Warrants will be exercisable until the earlier of April 7, 2027, or 30 days following the publication by the Issuer that the VITESSE Phase 3 study has met its primary endpoint as further described in the Terms and Conditions of the BS Warrants.
• French regulatory approvals may be required to increase the First and Second Pre-Funded Warrant Beneficial Ownership Limitation above 9.99%.

Future Outlook

The document outlines the terms of a private placement expected to close around April 7, 2025, suggesting continued investment and involvement by Baker Bros. Advisors in DBV Technologies.

Industry Context

Private placements are a common method for biotech companies to raise capital, especially when seeking funding for research and development or clinical trials. Baker Bros. is a well-known healthcare investor, so their investment could signal positive sentiment towards DBV Technologies' prospects in the biotech industry.

Comparison to Industry Standards

• Similar private placements in the biotech industry often involve warrants or options to purchase shares at a later date.
• The specific terms, such as the exercise price and expiration date, are typical for these types of transactions.
• Baker Bros. is a well-known healthcare investor, so their investment could signal positive sentiment towards DBV Technologies' prospects in the biotech industry.

Stakeholder Impact

• Shareholders may view the investment positively, as it provides DBV Technologies with additional capital.
• Employees may benefit from the increased financial stability of the company.
• The investment could support the development and commercialization of DBV Technologies' products, potentially benefiting patients.

Next Steps

• The private placement is expected to close on or around April 7, 2025.
• Exercise of the warrants will depend on market conditions, regulatory approvals, and the company's performance.
• The BS Warrants will be exercisable until the earlier of April 7, 2027, or 30 days following the publication by the Issuer that the VITESSE Phase 3 study has met its primary endpoint.

Key Dates

Keywords

DBV Technologies, Baker Bros. Advisors, pre-funded warrants, private placement, securities, investment, warrants, ordinary shares